Related Experiment Video
Updated: Aug 12, 2025

In Vitro Thrombosis Test for Ventricular Assist Devices
Published on: March 21, 2025
Thromboprophylaxis in Patients With Fontan Circulation
Jef Van den Eynde1, Mathias Possner2, Fares Alahdab3
1Helen B. Taussig Heart Center, The Johns Hopkins Hospital and School of Medicine, Baltimore, Maryland, USA; Department of Cardiovascular Diseases, University Hospitals Leuven and Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium. Electronic address: https://twitter.com/JefVandenEynde.
For Fontan circulation patients, aspirin, warfarin, and non-vitamin K oral anticoagulants (NOACs) reduce thromboembolic events. While all are effective, aspirin may offer the most favorable safety profile in this population.
Area of Science:
- Cardiology
- Hematology
- Pharmacology
Background:
- Optimal thromboprophylaxis strategy for Fontan circulation remains undetermined.
- Patients with Fontan circulation are at increased risk for thromboembolic events.
Purpose of the Study:
- To compare the efficacy and safety of aspirin, warfarin, and non-vitamin K oral anticoagulants (NOACs) for thromboprophylaxis in Fontan circulation patients.
- To identify the most effective and safest antithrombotic agent through a network meta-analysis.
Main Methods:
- A systematic literature search identified 21 studies published by February 2022.
- Frequentist network meta-analyses were performed to assess thromboembolic events and major bleeding rates.
- Treatment rankings were determined using probability (P) scores to evaluate overall treatment profiles.
Main Results:
- Aspirin, warfarin, and NOACs significantly reduced thromboembolic events compared to no thromboprophylaxis.
- No significant differences in major bleeding rates were observed among aspirin, warfarin, and NOACs.
- NOACs demonstrated the highest probability score for preventing thromboembolic events, though aspirin showed a favorable overall profile.
Conclusions:
- Aspirin, warfarin, and NOACs are effective in reducing thromboembolic risk in Fontan circulation patients.
- The study supports the safety and efficacy of NOACs, despite limitations in patient numbers and study heterogeneity.
- Aspirin emerged as a potentially favorable option, warranting further investigation.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Venous Thrombosis I: Introduction

